Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma

MEGAN E. HERCEG, ATHANASIOS C. TSIATIS, JENNIFER L. HALPERN, GINGER E. HOLT, HERBERT S. SCHWARTZ, VICKI L. KEEDY and JUSTIN M.M. CATES
Anticancer Research August 2009, 29 (8) 2913-2917;
MEGAN E. HERCEG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATHANASIOS C. TSIATIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JENNIFER L. HALPERN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GINGER E. HOLT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HERBERT S. SCHWARTZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VICKI L. KEEDY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUSTIN M.M. CATES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: justin.m.cates@vanderbilt.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Cyclooxygenase 2 (COX2) expression is up-regulated and associated with adverse prognosis in select types of carcinoma. Although not extensively studied in skeletal or soft tissue sarcoma, expression of COX2 has been described in a variable number of gynecological and non-gynecological leiomyosarcomas. In this study, the prevalence and prognostic implications of COX2 expression in leiomyosarcoma were evaluated further. Materials and Methods: Immunohistochemical stains for COX2 were performed on 33 samples of soft tissue leiomyosarcoma and tested for their association with clinicopathological parameters and patient outcome. Results: COX2 staining was limited to tumor cells surrounding areas of tumor necrosis in 6 cases. There were no statistically significant correlations with the clinicopathological parameters studied, including local recurrence, distant metastasis, or disease-specific death. Conclusion: The low frequency, restricted distribution and absence of prognostic implications of COX2 expression soft tissue leiomyosarcoma suggest that this enzyme may not be a useful pharmacological target in this clinical setting.

  • COX2
  • leiomyosarcoma
  • immunohistochemistry
  • tumor necrosis

Non-gynecological leiomyosarcomas (LMS) arising in the retroperitoneum and deep soft tissues of the extremities generally portend an unfavorable outcome (1-4). Pathological features typically associated with poor prognosis include histological grade, tumor size, and anatomic location (5). Complete surgical resection combined with perioperative adjuvant radiation therapy is currently considered the optimal therapy for LMS (4). However, disease recurrence is common. Although the Scandinavian Sarcoma Group has recently reported 10-year disease-free and overall survival rates of 66% and 49% for patients with localized disease at presentation (5), most other groups have shown much lower rates of disease control (4).

Whereas cyclooxygenase 1 shows ubiquitous and constitutive expression in many human tissues, cyclooxygenase 2 (COX2) expression in non-neoplastic tissue is extremely limited and is typically induced by proinflammatory or mitogenic stimuli such as cytokines, growth factors, oncogenes and endotoxins (6). Since COX2 is up-regulated in a number of different types of carcinoma and correlates with adverse clinical outcome for some tumor types, it has been implicated as being important during carcinogenesis or disease progression, although the mechanisms involved are unknown (7, 8). COX2 may promote neoplasia through inhibition of tumor cell apoptosis, augmentation of angiogenic potential, or suppression of the host immune response via down-regulation of natural killer T-cell function (9). Given the availability of specific inhibitors of COX2 activity, much work has studied this enzyme as a target for chemopreventative therapy (7).

Other than Kaposi's sarcoma and some pediatric sarcomas, COX2 expression has not been studied extensively in mesenchymal neoplasms (10-13). Previous reports of COX2 expression in some cases of uterine and extrauterine LMS prompted us to determine the prevalence of COX2 expression in a larger cohort of LMS of soft tissue (12, 13).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Correlation of clinical features with COX2 staining in soft tissue leiomyosarcoma.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Correlation of pathological findings with COX2 staining in soft tissue leiomyosarcoma.

Materials and Methods

Surgical pathology archives were searched for cases of primary LMS of deep soft tissue. Cases arising in subcutaneous tissue or involving viscera, including the female genital tract, were specifically excluded. Cases that showed nuclear staining for estrogen receptor α or progesterone receptor were considered LMS of gynecological type and excluded from the study. Clinicopathological parameters, including patient age, sex, anatomic site of primary tumor, tumor size, histologic grade, American Joint Committee on Cancer (AJCC) TNM stage (14), presence of and site of metastatic disease, and adjuvant therapy administered were recorded through a retrospective chart review. In addition, intervals from surgical resection to adverse events (defined as local recurrence, metastasis, or tumor-related death) or last clinical follow-up were also recorded.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Association of COX2 staining in soft tissue leiomyosarcoma with patient outcomes.

Thirty-three cases were retrieved. The original hematoxylin and eosin-stained slides were reviewed and blocks were selected for immunohistochemistry. Tumors were graded using the French Federation of Cancer Centers System (15). Formalin-fixed, paraffin-embedded tissue sections were pretreated in EDTA buffer in a steamer for 25 min. Following a 15 min cooling period, slides were incubated with a 1:75 dilution of rabbit polyclonal anti-COX2 antibody (PGHS-2; Oxford Biomedical Research Inc, Oxford, MI, USA) for 1 hour at room temperature. Specific antibody binding was detected using an LSAB2 kit according to the manufacturer's recommendations (Dako, Carpinteria, CA, USA). COX2 staining was scored using the Allred system (16). An Allred staining index ≥2 was considered positive for statistical analysis. Statistical analyses were performed using standard univariate methods (17). Differences in Kaplan-Meier disease-free and overall survival curves were evaluated using the log-rank test statistic (Prism v5; GraphPad Software, Inc. La Jolla, CA, USA). This study was approved by the Institutional Review Board at Vanderbilt University.

Results

Clinicopathological data recorded for 33 cases of primary soft tissue LMS are summarized in Tables I and II. Median age at tumor resection was 58 years (range 22-86 years). Neoadjuvant radiation therapy was administered to 7 patients; one additional patient received preoperative chemotherapy. Median length of follow-up was 23.4 months (range 6 months to 13 years). During this follow-up interval, 14 patients (42%) died of disease and 20 patients (61%) developed recurrent disease. Distant metastasis occurred in 14 patients (42%) a median of 9.6 months (range 4.5 months to 2.5 years) after surgical resection; metastatic disease was detected during initial staging studies in 3 additional patients. Six patients (18%) developed local tumor recurrence (median interval 19.2 months, range 10.4 months to 5.0 years).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Soft tissue leiomyosarcoma is typically negative for COX2 staining by immunohistochemistry (A, H&E, bar=1 mm; B, COX2). In a minority of cases, immunoreactivity is strictly limited to tumor cells surrounding areas of tumor necrosis (C, H&E; D, COX2).

COX2 immunoreactivity was detected in 6 out of 33 cases (18%) and was limited to cells adjacent to areas of ischemic or coagulative tumor necrosis (Table II), corresponding to Allred proportion scores of 1 (4 cases) and 2 (2 cases). Within these foci, however, Allred intensity scores for COX2 were intermediate (5 cases) or strong (1 case) (Figure 1). Accordingly, COX2 staining was seen exclusively in tumors of intermediate to high histological grade and AJCC TNM stage; these associations did not reach statistical significance, however (Table II). Additionally, no significant associations between COX2 staining and adverse events (Table III), tumor size, patient age, sex, anatomic site, or exposure to neoadjuvant therapy were observed in this relatively small study sample. Median overall and disease-free survival for patients with COX2-immunopositive tumors was 34.0 months and 24.3 months, respectively; the corresponding survival intervals for patients with COX2-negative tumors were 37.2 and 22.8 months. Log rank analysis of Kaplan-Meier curves disclosed no significant differences in disease-free or overall survival according to COX2 status, neither for the entire study cohort nor after substratification by presence or absence of tumor necrosis, AJCC TNM stage, or histological grade (data not shown).

Discussion

COX2 expression is associated with negative clinical outcomes in carcinomas from a variety of anatomic sites (13, 18-22). However, its expression has not been studied extensively in mesenchymal neoplasms. Preliminary evidence suggests that while COX2 is expressed in a majority of osteosarcomas, rhabdomyosarcomas, Ewing sarcoma/primitive neuroectodermal tumors, and gastrointestinal stromal tumors, there is correlation to clinicopathological features or prognosis (10, 11, 23). COX2 expression has also been demonstrated in a subset of uterine LMS (13), which led us to evaluate further whether it is detectable in non-gynecological LMS arising in soft tissue.

No soft tissue LMS was diffusely positive for COX2 in our study population. Instead, COX2 immunostaining in LMS was strictly localized to neoplastic cells surrounding areas of tumor necrosis. In a study of 103 soft tissue sarcomas of various histological type, Lassus et al. found that approximately 50% stained for COX2 (12). Similar to our findings, immunoreactivity was limited to areas adjacent to tumor necrosis in over a third of these COX2-positive cases. Of the 19 LMS included in this prior study, 8 (42%) demonstrated COX2 expression (12). However, only one case exhibited strong staining throughout the tumor and two other cases displayed weak but diffuse staining. Thus, 5 out of the 19 LMS in this previous study showed the same spatial expression pattern seen in our samples. Comparisons of COX2-positive and -negative tumors in the current study and that of Lassus et al. disclosed no significant differences in the clinicopathological parameters evaluated, including disease-free or overall survival.

The spatial relationship between COX2 immunoreactivity and coagulative tumor necrosis has been demonstrated previously in some other tumor types. Wolff et al. noted a rim of COX2-immunopositive tumor cells surrounding necrotic carcinomas of the lung (24). A similar pattern of COX2 expression has also been demonstrated in glioma (25-27). One possible explanation for this phenomenon is induction of COX2 expression in tumor cells by regional hypoxia or an inflammatory response (28, 29).

Given the lack of prognostic correlation and limited distribution of expression of COX2 in soft tissue LMS, it is unlikely that such a finding indicates COX2 as a useful pharmacological target in this clinical setting.

Acknowledgements

This study was funded by an intradepartmental clinical translational research award (ACT). The authors thank Jean McClure and Lesley Albert for technical and editorial assistance.

  • Received March 26, 2009.
  • Revision received May 26, 2009.
  • Accepted May 27, 2009.
  • Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Gustafson P
    : Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259: 1-31, 1994.
    OpenUrlPubMed
    1. Gustafson P,
    2. Willen H,
    3. Baldetorp B,
    4. Ferno M,
    5. Akerman M,
    6. Rydholm A
    : Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer 70: 114-119, 1992.
    OpenUrlCrossRefPubMed
    1. Hashimoto H,
    2. Daimaru Y,
    3. Tsuneyoshi M,
    4. Enjoji M
    : Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer 57: 2077-2088, 1986.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Massi D,
    2. Beltrami G,
    3. Mela MM,
    4. Pertici M,
    5. Capanna R,
    6. Franchi A
    : Prognostic factors in soft tissue leiomyosarcoma of the extremities: A retrospective analysis of 42 cases. Eur J Surg Oncol 30: 565-572, 2004.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Svarvar C,
    2. Bohling T,
    3. Berlin O,
    4. Gustafson P,
    5. Folleras G,
    6. Bjerkehagen B,
    7. Domanski HA,
    8. Sundby Hall K,
    9. Tukiainen E,
    10. Blomqvist C
    : Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer 109: 282-291, 2007.
    OpenUrlPubMed
  4. ↵
    1. Thomas B,
    2. Berenbaum F,
    3. Humbert L,
    4. Bian H,
    5. Bereziat G,
    6. Crofford L,
    7. Olivier JL
    : Critical role of C/EBPδ and C/EBPβ factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1β in articular chondrocytes. Eur J Biochem 267: 6798-6809, 2000.
    OpenUrlPubMed
  5. ↵
    1. Dannenberg AJ,
    2. Altorki NK,
    3. Boyle JO,
    4. Dang C,
    5. Howe LR,
    6. Weksler BB,
    7. Subbaramaiah K
    : Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-551, 2001.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Turini ME,
    2. DuBois RN
    : Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53: 35-57, 2002.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Williams CS,
    2. Mann M,
    3. DuBois RN
    : The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Dickens DS,
    2. Kozielski R,
    3. Khan J,
    4. Forus A,
    5. Cripe TP
    : Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 5: 356-364, 2002.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Dickens DS,
    2. Kozielski R,
    3. Leavey PJ,
    4. Timmons C,
    5. Cripe TP
    : Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 25: 282-285, 2003.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Lassus P,
    2. Ristimaki A,
    3. Huuhtanen R,
    4. Tukiainen E,
    5. Asko-Seljavaara S,
    6. Andersson LC,
    7. Miettinen M,
    8. Blomqvist C,
    9. Haglund C,
    10. Bohling T
    : Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentiation. Anticancer Res 25: 2669-2674, 2005.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Raspollini MR,
    2. Amunni G,
    3. Villanucci A,
    4. Paglierani M,
    5. Taddei GL
    : Cyclooxygenase-2 expression in uterine leiomyosarcomas. J Chemother 16: 577-581, 2004.
    OpenUrlPubMed
  12. ↵
    1. Greene FL,
    2. Page DL,
    3. Fleming ID,
    4. Fritz AG,
    5. Balch CM,
    6. Haller DG,
    7. Morrow M
    : AJCC Cancer Staging Manual. New York, Springer-Verlag., pp. 193-200, 2002.
  13. ↵
    1. Fletcher CDM,
    2. Unni KK,
    3. Mertens F
    1. Fletcher CDM,
    2. Rydholm A,
    3. Sinder S,
    4. Sundaram M,
    5. Coindre JM
    : In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (eds.). Lyon, IARC Press, pp. 12-18, 2002.
  14. ↵
    1. Allred DC,
    2. Clark GM,
    3. Elledge R,
    4. Fuqua SA,
    5. Brown RW,
    6. Chamness GC,
    7. Osborne CK,
    8. McGuire WL
    : Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kirkman TW
    : Statistics to use. http://www.physics.csbsju.edu/stats (accessed 23 Feb 2009).
  16. ↵
    1. Huang M,
    2. Stolina M,
    3. Sharma S,
    4. Mao JT,
    5. Zhu L,
    6. Miller PW,
    7. Wollman J,
    8. Herschman H,
    9. Dubinett SM
    : Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998.
    OpenUrlAbstract/FREE Full Text
    1. Ohno R,
    2. Yoshinaga K,
    3. Fujita T,
    4. Hasegawa K,
    5. Iseki H,
    6. Tsunozaki H,
    7. Ichikawa W,
    8. Nihei Z,
    9. Sugihara K
    : Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 91: 1876-1881, 2001.
    OpenUrlCrossRefPubMed
    1. Tsujii M,
    2. Kawano S,
    3. DuBois RN
    : Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
    OpenUrlAbstract/FREE Full Text
    1. Tucker ON,
    2. Dannenberg AJ,
    3. Yang EK,
    4. Zhang F,
    5. Teng L,
    6. Daly JM,
    7. Soslow RA,
    8. Masferrer JL,
    9. Woerner BM,
    10. Koki AT,
    11. Fahey TJ
    : Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Madaan S,
    2. Abel PD,
    3. Chaudhary KS,
    4. Hewitt R,
    5. Stott MA,
    6. Stamp GW,
    7. Lalani EN
    : Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 86: 736-741, 2000.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Stewart AE,
    2. Heslin MH,
    3. Arch J,
    4. Jhala N,
    5. Ragland B,
    6. Gomez F,
    7. Bland KI,
    8. Arnoletti JP
    : Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors. J Gastrointest Surg 10: 315-319, 2006.
    OpenUrlPubMed
  19. ↵
    1. Wolff H,
    2. Saukkonen K,
    3. Anttila S,
    4. Karjalainen A,
    5. Vainio H,
    6. Ristimaki A
    : Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Deininger MH,
    2. Weller M,
    3. Streffer J,
    4. Mittelbronn M,
    5. Meyermann R
    : Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol 98: 240-244, 1999.
    OpenUrlCrossRefPubMed
    1. Shono T,
    2. Tofilon PJ,
    3. Bruner JM,
    4. Owolabi O,
    5. Lang FF
    : Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61: 4375-4381, 2001.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Sminia P,
    2. Stoter TR,
    3. van der Valk P,
    4. Elkhuizen PH,
    5. Tadema TM,
    6. Kuipers GK,
    7. Vandertop WP,
    8. Lafleur MV,
    9. Slotman BJ
    : Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol 131: 653-661, 2005.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Royds JA,
    2. Dower SK,
    3. Qwarnstrom EE,
    4. Lewis CE
    : Response of tumour cells to hypoxia: role of p53 and NF-κB. Mol Pathol 51: 55-61, 1998.
    OpenUrlAbstract
  23. ↵
    1. Schmedtje JF Jr.,
    2. Ji YS,
    3. Liu WL,
    4. DuBois RN,
    5. Runge MS
    : Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 29 (8)
Anticancer Research
Vol. 29, Issue 8
August 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma
MEGAN E. HERCEG, ATHANASIOS C. TSIATIS, JENNIFER L. HALPERN, GINGER E. HOLT, HERBERT S. SCHWARTZ, VICKI L. KEEDY, JUSTIN M.M. CATES
Anticancer Research Aug 2009, 29 (8) 2913-2917;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma
MEGAN E. HERCEG, ATHANASIOS C. TSIATIS, JENNIFER L. HALPERN, GINGER E. HOLT, HERBERT S. SCHWARTZ, VICKI L. KEEDY, JUSTIN M.M. CATES
Anticancer Research Aug 2009, 29 (8) 2913-2917;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Inhibiting miR-33b-5p Enhances Chemoresistance in Lung Adenocarcinoma by Targeting YWHAH to Regulate Epithelial-mesenchymal Transition
  • Relationship Between Mediterranean Diet, Cardiovascular Risk Factors, and Meningiomas: A Retrospective Study
  • PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire